Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1990 Feb;61(2):311–315. doi: 10.1038/bjc.1990.59

A phase III randomised trial of cisplatinum, methotrextate, cisplatinum + methotrexate and cisplatinum + 5-FU in end stage squamous carcinoma of the head and neck. Liverpool Head and Neck Oncology Group.

PMCID: PMC1971415  PMID: 2178667

Abstract

We describe a phase III trial on 200 patients with end stage squamous cell carcinoma of the head and neck. The patients were randomised to one of four treatment arms: cisplatinum alone, methotrexate alone, cisplatinum + 5-FU and cisplatinum + methotrexate. There was no significant difference in the response rates, but the survival of the cisplatinum arm was significantly better than that of the methotrexate arm. The survival of patients receiving cisplatinum as a single agent was longer than that of patients receiving cisplatinum in combination with methotrexate or 5-FU, but not significantly so. Nausea/vomiting and anaemia were significantly more common in the cisplatinum arms than in the methotrexate arm, but the toxicity of combination regimens was not significantly greater than that of cisplatinum used as a single agent.

Full text

PDF
311

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Amer M. H., Izbicki R. M., Vaitkevicius V. K., Al-Sarraf M. Combination chemotherapy with cis-diamminedichloroplatinum, oncovin, and bleomycin (COB) in advanced head and neck cancer: phase II. Cancer. 1980 Jan 15;45(2):217–223. doi: 10.1002/1097-0142(19800115)45:2<217::aid-cncr2820450204>3.0.co;2-8. [DOI] [PubMed] [Google Scholar]
  2. Bertino J. R., Boston B., Capizzi R. L. The role of chemotherapy in the management of cancer of the head and neck: a review. Cancer. 1975 Aug;36(2):752–758. doi: 10.1002/1097-0142(197508)36:2+<752::aid-cncr2820360820>3.0.co;2-h. [DOI] [PubMed] [Google Scholar]
  3. Campbell J. B., Dorman E. B., Helliwell T. R., McCormick M., Miles J., Morton R. P., Rugman F., Stell P. M., Stoney P. J., Vauhan E. D. Factors predicting response of end stage squamous cell carcinoma of the head and neck to cisplatinum. Clin Otolaryngol Allied Sci. 1987 Jun;12(3):167–176. doi: 10.1111/j.1365-2273.1987.tb00183.x. [DOI] [PubMed] [Google Scholar]
  4. Decker D. A., Drelichman A., Jacobs J., Hoschner J., Kinzie J., Loh J. J., Weaver A., Al-Sarraf M. Adjuvant chemotherapy with cis-diamminodichloroplatinum II and 120-hour infusion 5-fluorouracil in Stage III and IV squamous cell carcinoma of the head and neck. Cancer. 1983 Apr 15;51(8):1353–1355. doi: 10.1002/1097-0142(19830415)51:8<1353::aid-cncr2820510805>3.0.co;2-i. [DOI] [PubMed] [Google Scholar]
  5. Field J. K., Lamothe A., Spandidos D. A. Clinical relevance of oncogene expression in head and neck tumours. Anticancer Res. 1986 Jul-Aug;6(4):595–600. [PubMed] [Google Scholar]
  6. Goldsmith M. M., Cresson D. S., Postma D. S., Askin F. B., Pillsbury H. C. Significance of ploidy in laryngeal cancer. Am J Surg. 1986 Oct;152(4):396–402. doi: 10.1016/0002-9610(86)90311-9. [DOI] [PubMed] [Google Scholar]
  7. Hong W. K., Schaefer S., Issell B., Cummings C., Luedke D., Bromer R., Fofonoff S., D'Aoust J., Shapshay S., Welch J. A prospective randomized trial of methotrexate versus cisplatin in the treatment of recurrent squamous cell carcinoma of the head and neck. Cancer. 1983 Jul 15;52(2):206–210. doi: 10.1002/1097-0142(19830715)52:2<206::aid-cncr2820520204>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
  8. Jacobs C., Meyers F., Hendrickson C., Kohler M., Carter S. A randomized phase III study of cisplatin with or without methotrexate for recurrent squamous cell carcinoma of the head and neck. A Northern California Oncology Group study. Cancer. 1983 Nov 1;52(9):1563–1569. doi: 10.1002/1097-0142(19831101)52:9<1563::aid-cncr2820520904>3.0.co;2-r. [DOI] [PubMed] [Google Scholar]
  9. Kish J. A., Ensley J. F., Jacobs J., Weaver A., Cummings G., Al-Sarraf M. A randomized trial of cisplatin (CACP) + 5-fluorouracil (5-FU) infusion and CACP + 5-FU bolus for recurrent and advanced squamous cell carcinoma of the head and neck. Cancer. 1985 Dec 15;56(12):2740–2744. doi: 10.1002/1097-0142(19851215)56:12<2740::aid-cncr2820561203>3.0.co;2-y. [DOI] [PubMed] [Google Scholar]
  10. Kish J. A., Weaver A., Jacobs J., Cummings G., Al-Sarraf M. Cisplatin and 5-fluorouracil infusion in patients with recurrent and disseminated epidermoid cancer of the head and neck. Cancer. 1984 May 1;53(9):1819–1824. doi: 10.1002/1097-0142(19840501)53:9<1819::aid-cncr2820530903>3.0.co;2-r. [DOI] [PubMed] [Google Scholar]
  11. Miller A. B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer. 1981 Jan 1;47(1):207–214. doi: 10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  12. Morton R. P., Rugman F., Dorman E. B., Stoney P. J., Wilson J. A., McCormick M., Veevers A., Stell P. M. Cisplatinum and bleomycin for advanced or recurrent squamous cell carcinoma of the head and neck: a randomised factorial phase III controlled trial. Cancer Chemother Pharmacol. 1985;15(3):283–289. doi: 10.1007/BF00263902. [DOI] [PubMed] [Google Scholar]
  13. Muggia F. M., Rozencweig M., Louie A. E. Role of chemotherapy in head and neck cancer: systemic use of single agents and combinations in advanced disease. Head Neck Surg. 1980 Jan-Feb;2(3):196–205. doi: 10.1002/hed.2890020305. [DOI] [PubMed] [Google Scholar]
  14. Peto R., Pike M. C., Armitage P., Breslow N. E., Cox D. R., Howard S. V., Mantel N., McPherson K., Peto J., Smith P. G. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br J Cancer. 1976 Dec;34(6):585–612. doi: 10.1038/bjc.1976.220. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Vogl S. E., Kaplan B. H. Chemotherapy of advanced head and neck cancer with methotrexate, bleomycin, and cis-diamminedichloroplatinum II in an effective outpatient schedule. Cancer. 1979 Jul;44(1):26–31. doi: 10.1002/1097-0142(197907)44:1<26::aid-cncr2820440105>3.0.co;2-w. [DOI] [PubMed] [Google Scholar]
  16. Wittes R., Heller K., Randolph V., Howard J., Vallejo A., Farr H., Harrold C., Gerold F., Shah J., Spiro R. cis-Dichlorodiammineplatinum(II)-based chemotherapy as initial treatment of advanced head and neck cancer. Cancer Treat Rep. 1979 Sep-Oct;63(9-10):1533–1538. [PubMed] [Google Scholar]
  17. Wolf G. T., Makuch R. W., Baker S. R. Predictive factors for tumor response to preoperative chemotherapy in patients with head and neck squamous carcinoma. The Head and Neck Contracts Program. Cancer. 1984 Dec 15;54(12):2869–2877. doi: 10.1002/1097-0142(19841215)54:12<2869::aid-cncr2820541210>3.0.co;2-n. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES